莱美药业：注射用氨曲南（0.5g）获药品补充申请批准通知书

Core Viewpoint - Recently, the company received approval from the National Medical Products Administration for the injectable Amikacin (specification: 0.5g), which has passed the consistency evaluation for generic injectable drugs and includes changes to quality standards and packaging materials [1] Group 1 - The injectable Amikacin is indicated for the treatment of various infections, with 12 manufacturers having passed the consistency evaluation to date [1] - The sales revenue for injectable Amikacin in the Chinese hospital market is projected to be 259 million yuan, 220 million yuan, and 40 million yuan for the years 2023, 2024, and the first half of 2025, respectively [1] - The approval is expected to facilitate market expansion for the product, although there are uncertainties regarding production and sales [1]